Albagha Omar M E, Ralston Stuart H
Department of Medicine and Therapeutics, University of Aberdeen Medical School, Aberdeen AB25 2ZD, UK.
Endocrinol Metab Clin North Am. 2003 Mar;32(1):65-81, vi. doi: 10.1016/s0889-8529(02)00059-2.
Osteoporosis has a strong genetic component, and clinical studies have shown that heritable factors play a key role in regulating bone mineral density, ultrasound properties of bone, skeletal geometry, and bone turnover and contribute to the pathogenesis of osteoporotic fracture. In most cases, osteoporosis is caused by the combined effects of several different genes and their interaction with environmental influences, but it can occasionally occur as the result of mutations in a single gene. Genes that have been implicated in the regulation of bone mass in humans include the genes encoding lipoprotein receptor-related protein 5, sclerostin, transforming growth factor beta-1, collagen Ialpha1, vitamin D receptor, tumor necrosis factor receptor 2, and the estrogen receptor alpha. From a clinical standpoint, advances in knowledge about the genetic basis of osteoporosis are important because they offer the prospect of developing genetic markers for the assessment of fracture risk and the opportunity to identify molecules that will be used as targets for the design of new drugs for the prevention and treatment of bone disease.
骨质疏松症具有很强的遗传因素,临床研究表明,遗传因素在调节骨矿物质密度、骨的超声特性、骨骼几何形状和骨转换中起关键作用,并促成骨质疏松性骨折的发病机制。在大多数情况下,骨质疏松症是由几种不同基因的综合作用及其与环境影响的相互作用引起的,但偶尔也可能是单个基因突变的结果。与人类骨量调节有关的基因包括编码脂蛋白受体相关蛋白5、硬化蛋白、转化生长因子β-1、胶原蛋白Iα1、维生素D受体、肿瘤坏死因子受体2和雌激素受体α的基因。从临床角度来看,关于骨质疏松症遗传基础的知识进展很重要,因为它们为开发用于评估骨折风险的遗传标记物提供了前景,也为识别将用作预防和治疗骨病新药设计靶点的分子提供了机会。